1. Australia Stocks

  2. •

    Health technology

  3. •

    Medical specialties
CLEO Diagnostics Ltd

CLEO Diagnostics Ltd

AASX:COV
0.31
AUD
-0.01
(-3.17%)
-0.04EPS
68.56MMarket Cap
CLEO Diagnostics Ltd
ASX:COV
(Australian Securities Exchange)

Recent

price

0.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

2023
2024
2025
2026
AUD
- -
- -
- -
- -
Revenue per Share
-0.07
-0.03
-0.03
-0.04
Basic EPS, GAAP
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
-0.02
0.08
0.05
0.04
Book Value per Share
-0.03
0.08
0.04
0.03
Tangible Book Value per Share
26
117
129
133
Basic Weighted Avg Shares
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
Depreciation Expense
-2
-4
-4
-6
Net Income, GAAP
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-1
9
5
5
Working Capital
- -
- -
- -
- -
LT Debt
-1
11
6
5
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-48.64
-109.48
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-14.13%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
48.44%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.03
2025
- -
- -
-0.03
2026
- -
- -
-0.04

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
CLEO Diagnostics Ltd. is a medical diagnostics/devices company which mainly focuses on the development of non-invasive blood based IVD tests to detect the presence, and recurrence, of ovarian cancer. It developed a three-phased product development strategy that will deliver three related tests for ovarian cancer detection: Triage Test-a pre-surgical test, Recurrence Test-a post-surgical test and Screening Test-a screening test to identify early-stage ovarian cancer. The company was founded on November 30, 2021 and is headquartered in Melbourne, Australia.